Observational studyThe journal of allergy and clinical immunology. In practice2026
Respiratory Biologics Utilization, Prescription Predictors, and Outcomes in Patients With Asthma and Comorbid Overweight or Obesity.
Observational study in The journal of allergy and clinical immunology. In practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Coexisting Asthma and Diabetes Are Associated With Adverse Metabolic and Inflammatory Profiles.Diabetes, obesity & metabolism · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundPatients with asthma and elevated body mass index have higher baseline exacerbation risk and vulnerability to corticosteroid adverse effects. Yet evidence on the use and efficacy of respiratory biologics, which reduce these risks, in patients with obesity is lacking.
objectiveTo test the hypothesis that respiratory biologics are underused in eligible patients with obesity.
methodsThis is a retrospective observational analysis of adult patients with active, moderate to severe asthma and with a body mass index of 25 kg/m
resultsWe included 5,805 patients with asthma and overweight or obesity who were eligible for a biologic. Of these, 11.9% were prescribed biologics. Of the biologic-eligible cohort, 59.8% had obesity and 10.4% of those patients were prescribed biologics. In adjusted analyses, obesity reduced prescription odds and time to initiation. Subspecialist care was the strongest prescription predictor. Annualized exacerbation rates significantly declined across type 2 biologics users with obesity. Use of obesity-adjusted eosinophil criteria expanded biologics eligibility by 11.3% without clear exacerbation benefit.
conclusionsOnly a fraction of eligible patients with asthma and comorbid obesity receive biologics despite meeting type 2 biomarker criteria, compared with patients with overweight or healthy weight. These data may substantially inform health services research and therapeutic interventions to improve asthma management.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.